Literature DB >> 20509035

S100P: a novel therapeutic target for cancer.

Thiruvengadam Arumugam1, Craig D Logsdon.   

Abstract

S100P expression is described in many different cancers, and its expression is associated with drug resistance, metastasis, and poor clinical outcome. S100P is member of the S100 family of small calcium-binding proteins that have been reported to have either intracellular or extracellular functions, or both. Extracellular S100P can bind with the receptor for advanced glycation end products (RAGE) and activate cellular signaling. Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis. S100P is specifically expressed in cancer cells in the adult. Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, and can aid in the diagnosis of cancer by cytological examination. The expression of S100P in cancer cells has been related to hypomethylation of the gene. Multiple studies have confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and different blockers are being developed including small molecules and antagonist peptides. This review summarizes the role and significance of S100P in different cancers.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20509035      PMCID： PMC4041611          DOI： 10.1007/s00726-010-0496-4

Source DB:  PubMed          Journal:  Amino Acids        ISSN： 0939-4451            Impact factor:   3.520


  64 in total

1.  The crystal structure at 2A resolution of the Ca2+ -binding protein S100P.

Authors:  Hongmei Zhang; Guozheng Wang; Yi Ding; Zhilong Wang; Roger Barraclough; Philip S Rudland; David G Fernig; Zihe Rao
Journal:  J Mol Biol       Date:  2003-01-24       Impact factor: 5.469

2.  S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).

Authors:  Thiruvengadam Arumugam; Diane M Simeone; Ann Marie Schmidt; Craig D Logsdon
Journal:  J Biol Chem       Date:  2003-11-14       Impact factor: 5.157

3.  Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro.

Authors:  A Leone-Bay; H Leipold; D Sarubbi; B Variano; T Rivera; R A Baughman
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 4.  NF-kappaB in cancer: from innocent bystander to major culprit.

Authors:  Michael Karin; Yixue Cao; Florian R Greten; Zhi-Wei Li
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

5.  S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties.

Authors:  T Becker; V Gerke; E Kube; K Weber
Journal:  Eur J Biochem       Date:  1992-07-15

6.  Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.

Authors:  Miki Okada; Hiroshi Tokumitsu; Yasuo Kubota; Ryoji Kobayashi
Journal:  Biochem Biophys Res Commun       Date:  2002-04-12       Impact factor: 3.575

7.  Retinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells.

Authors:  Rong-Yaun Shyu; Shiang-Long Huang; Shun-Yuan Jiang
Journal:  J Biomed Sci       Date:  2003 May-Jun       Impact factor: 8.410

8.  cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.

Authors:  Alan Mackay; Chris Jones; Tim Dexter; Ricardo L A Silva; Karen Bulmer; Allison Jones; Peter Simpson; Robert A Harris; Parmjit S Jat; A Munro Neville; Luiz F L Reis; Sunil R Lakhani; Michael J O'Hare
Journal:  Oncogene       Date:  2003-05-01       Impact factor: 9.867

9.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.

Authors:  Craig D Logsdon; Diane M Simeone; Charles Binkley; Thiruvengadam Arumugam; Joel K Greenson; Thomas J Giordano; David E Misek; Rork Kuick; Samir Hanash
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.

Authors:  Tatjana Crnogorac-Jurcevic; Edoardo Missiaglia; Ekaterina Blaveri; Rathi Gangeswaran; Melanie Jones; Benoit Terris; Eithne Costello; John P Neoptolemos; Nicholas R Lemoine
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996
View more
  39 in total

1.  LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P.

Authors:  Boon-Shing Tan; Min-Chi Yang; Shaifali Singh; Yu-Chi Chou; Hsin-Yi Chen; Ming-Yang Wang; Yi-Ching Wang; Ruey-Hwa Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

Review 2.  Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.

Authors:  Craig D Logsdon; Thiruvengadam Arumugam; Vijaya Ramachandran
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-09       Impact factor: 4.052

3.  Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.

Authors:  Lan He; Hongguang Bao; Jing Xue; Lihong Zheng; Qi Zhang; Lei Sun; Hongming Pan
Journal:  Tumour Biol       Date:  2014-05-30

4.  High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer.

Authors:  Xiangyu Wang; Tian Tian; Xukun Li; Meng Zhao; Yanhui Lou; Jingfeng Qian; Zhihua Liu; Hongyan Chen; Zhumei Cui
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 5.  The role of S100 proteins and their receptor RAGE in pancreatic cancer.

Authors:  Estelle Leclerc; Stefan W Vetter
Journal:  Biochim Biophys Acta       Date:  2015-10-03

6.  Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.

Authors:  Lei Dong; Fule Wang; Xiaona Yin; Ling Chen; Gang Li; Feiyan Lin; Wuhua Ni; Jianbo Wu; Rong Jin; Lei Jiang
Journal:  Mol Cell Biochem       Date:  2014-01-01       Impact factor: 3.396

7.  S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Sobeyda B Gomez; Ann M Schmidt; Craig D Logsdon
Journal:  Clin Cancer Res       Date:  2012-06-20       Impact factor: 12.531

8.  S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma.

Authors:  Lu-Nan Qi; Liang Ma; Fei-Xiang Wu; Yuan-Yuan Chen; Wan-Ting Xing; Zhi-Jun Jiang; Jian-Hong Zhong; Zu-Shun Chen; Wen-Feng Gong; Jia-Zhou Ye; Hong-Hao Li; Jin-Jie Shang; Bang-De Xiang; Le-Qun Li
Journal:  Hepatol Int       Date:  2021-01-25       Impact factor: 6.047

9.  Ca2+/S100 proteins act as upstream regulators of the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein).

Authors:  Seiko Shimamoto; Yasuo Kubota; Fuminori Yamaguchi; Hiroshi Tokumitsu; Ryoji Kobayashi
Journal:  J Biol Chem       Date:  2013-01-23       Impact factor: 5.157

Review 10.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.